Abstract 58P
Background
Vepdegestrant (ARV-471) is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. Based on results of the phase 2 cohort expansion (VERITAC) of a phase 1/2 study (NCT04072952), vepdegestrant 200 mg once daily (QD) was selected as the recommended phase 3 dose (RP3D). This phase 1 study (NCT05463952) investigated the safety, PK, and preliminary efficacy of vepdegestrant in Japanese patients with ER+/HER2- advanced breast cancer at the RP3D.
Methods
Patients with ER+/HER2- advanced breast cancer who were resistant to standard therapy or for whom no standard therapy was available or who had received ≥2 prior endocrine therapies in any setting were eligible. Vepdegestrant 200 mg was given QD with food. The primary endpoint was dose-limiting toxicities (DLTs) in cycle 1; secondary endpoints included safety, PK, and antitumor activity.
Results
Six female patients were treated; median age was 58 years (range: 47–62). Five patients received ≥3 prior regimens for advanced disease; 5 patients received prior CDK4/6 inhibitors. At the data cutoff (May 4, 2023), median treatment duration was 9.8 weeks (range: 6–28); 2 patients remained on treatment. No DLTs were observed. Four (66.7%) patients experienced adverse events (AEs); none led to dose reduction or discontinuation. Treatment-related AEs were abdominal discomfort, anemia, dizziness, increased alanine aminotransferase, increased aspartate aminotransferase, nausea, and pruritus (1 event each); all were grade 1 except anemia (grade 2). Geometric mean Cmax and AUC24 of vepdegestrant were 630.9 ng/mL and 10,400 ng•hr/mL after a single dose and 1056 ng/mL and 18,310 ng•hr/mL after multiple doses. Two patients demonstrated stable disease at week 24 assessment.
Conclusions
The RP3D of vepdegestrant 200 mg QD was well tolerated in Japanese patients with ER+/HER2- advanced breast cancer. Vepdegestrant will be evaluated in 2 global, randomized phase 3 studies in patients with ER+/HER2- advanced breast cancer: as second/third-line monotherapy in VERITAC-2 (NCT05654623) and as first-line therapy in combination with palbociclib in VERITAC-3 (NCT05909397).
Clinical trial identification
NCT05463952.
Editorial acknowledgement
Editorial support provided by Nathan Yardley, PhD, and Melissa Austin of Apollo Medical Communications, part of Helios Global Group, and funded by Arvinas Operations, Inc.
Legal entity responsible for the study
Pfizer, Inc.
Funding
Pfizer, Inc.
Disclosure
H. Iwata: Financial Interests, Personal, Advisory Board: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Sanofi; Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Pfizer, Sanofi, Taiho; Financial Interests, Personal and Institutional, Steering Committee Member: Chugai, Daiichi Sankyo, AstraZeneca, MSD, Amgen, Sanofi, Novartis, Pfizer, Kyowa Hakko Kirin; Financial Interests, Personal and Institutional, Local PI: Lilly, Bayer, Behringer, Nihon Kayaku. Y. Naito: Financial Interests, Personal, Invited Speaker, Speakers Bureau: Chugai, Pfizer, Eli Lilly, Eisai, AstraZeneca, PDR pharma, Novartis, Gardant, Ono, Takeda, Taiho, Bayer, Nihon Kayaku, Daiichi Sankyo, Bristol, MSD; Financial Interests, Personal, Funding: Roche; Financial Interests, Personal, Local PI: AbbVie, Boehringer Ingelheim, Ono, Chugai, Taiho, Pfizer, AstraZeneca, Gilead, Takeda; Financial Interests, Personal, Steering Committee Member: Daiichi Sankyo; Non-Financial Interests, Personal, Principal Investigator, JCOG: Natera. M. Hattori: Financial Interests, Personal, Speaker’s Bureau: Pfizer. K. Yonemori: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, Sanofi, Genmab, Gliad, OncoXerna, Takeda, Novartis, MSD; Financial Interests, Personal, Invited Speaker: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Ono, BMS, Boeringer Ingerheim, Daiichi Sankyo, Bayer, Jansen, Sanofi; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seagen, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirrin, Nihon Kayaku, Haihe. M. Aizawa, J. Yoshimitsu: Financial Interests, Personal, Full or part-time Employment: Pfizer R&D Japan. Y. Mori, Y. Umeyama: Financial Interests, Personal, Full or part-time Employment: Pfizer R&D Japan; Financial Interests, Personal, Stocks/Shares: Pfizer Inc. T. Mukohara: Financial Interests, Personal, Research Grant: Daiichi Sankyo, Sysmex, Eisai, MSD, Pfizer, Novartis, Sanofi, Chugai, AstraZeneca, Ono; Financial Interests, Personal, Speaker, Consultant, Advisor, Lecture fees: Eisai, Pfizer, Novartis, Chugai, Eli Lilly, AstraZeneca, Kyowa-Kirin, Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract